Jayme A. Huleatt
Ms. Huleatt received a Bachelor of Arts degree in Biology with a minor in Chemistry from West Chester University (West Chester, PA), a Master of Science degree in Microbiology from Rutgers The State University (New Brunswick, NJ), a Master of Business Administration from Rutgers The State University (Newark, NJ) and a Juris Doctor degree from The Catholic University of America, Columbus School of Law (Washington, DC).
Prior to beginning her legal career, Ms. Huleatt was employed by Hoffmann-LaRoche, Inc. (Nutley, NJ) as a research scientist at the Roche Institute of Molecular Biology and as a clinical research associate in the Medical Research rheumatology group.
Ms. Huleatt later joined the United States Patent & Trademark Office (USPTO) in the biotechnology Group 180 (now Group 1600) where she became a Primary Examiner and examined in the areas of immunology, recombinantly produced proteins and polypeptides, molecular biology/recombinant DNA processes, virology, microbiology, cell biology, enzymology with particular emphasis on tissue plasminogen activators, transgenic animal and plant technologies and products, and diagnostic methods and kits.
After leaving the USPTO, Ms. Huleatt worked at Vossius & Partner in Munich, Germany, as a US patent attorney providing patent advice regarding US patent law, rules, practice and procedures, and working with her European patent colleagues on European patent prosecution, oppositions and appeals in the biotechnology field.
Upon returning to the United States, Ms. Huleatt held patent attorney positions at Gunn, Lee, & Miller, LLP (San Antonio, TX), at the University of Texas Health Science Center (San Antonio, TX), Foley & Lardner, LLP (Washington, DC), Cooley LLP (Reston, VA & Washington, DC), Micromet, Inc. (acquired by Amgen, Inc.) (Rockville, MD), and Amgen, Inc.
Ms. Huleatt’s fields of technical expertise include biotechnology, biochemistry, protein chemistry, including applicable processes and products, pharmaceuticals, nutraceuticals, immunology (particularly antibody engineering, therapies and vaccines), diagnostic methods, transgenic animal and plant technologies and applications, and stem cell technologies.
Ms. Huleatt has extensive experience in all phases of intellectual property law practice, including patent preparation, filing and prosecution; infringement and validity analyses; and due diligence of patent portfolios, including analyses of commercialization, freedom-to-operate, strength of patent protection, regulatory exclusivities and effect and timing of generic market entry. Ms. Huleatt has in-depth expertise in USPTO rules and procedures and has extensive experience in international patent procurement, and has served as a USPTO patent practice expert. Ms. Huleatt provides strategic counseling to clients on US and foreign patent issues relevant to the overall prosecution strategy of clients’ patent portfolios.
Ms. Huleatt is currently a member in good standing of the Virginia and District of Columbia Bars, is registered to practice before the USPTO and is admitted to practice before the Court of Appeals for the Federal Circuit.